Evidence map›Paper›PMID 41322030›Full record

ArticleMedComm2025

Yin Yang 1 Promotes Antiprogrammed Cell Death-1 Resistance in Hepatocellular Carcinoma through Polypeptide N-Acetylgalactosaminyltransferase 16-Mediated Glycosylation of Programmed Death Ligand-1.

Shu-Sheng Lin, Gang Xiao, Qin-Qin Liu, Jia-Hao Xue, Zhi-Jun Chen, Hong-Hua Zhang, Xiang-Ping Zhu, Keng-Long Huang, Cai-Ni Yang, Ke Zhu and 2 more

Abstract read
In one paragraph

Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shu-Sheng LinDepartment of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
Gang XiaoDepartment of Thoracic Surgery Guangzhou First People's Hospital Guangzhou Medical University Guangzhou China.ORCID https://orcid.org/0000-0001-7784-4963
Qin-Qin LiuDepartment of Hepatobiliary Surgery Southwest Hospital Third Military Medical University (Army Medical University) Chongqing China.
Jia-Hao XueDepartment of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
Zhi-Jun ChenDepartment of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
Hong-Hua ZhangDepartment of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.ORCID https://orcid.org/0000-0001-6517-7649
Xiang-Ping ZhuDepartment of Oncology Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.
Keng-Long HuangDepartment of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
Cai-Ni YangDepartment of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.ORCID https://orcid.org/0009-0007-3622-1787
Ke ZhuDepartment of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
Hao-Ming LinDepartment of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
Rui ZhangDepartment of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) are widely used for treating hepatocellular carcinoma (HCC), yet their efficacy remains limited, with suboptimal response rates. The predictive power of the current biomarker, programmed death ligand-1 (PD-L1), is limited by detection variability and glycosylation, underscoring the need for complementary biomarkers to enhance predictive accuracy. In this study, mass spectrometry was employed to identify proteomic alterations in HCC tissues from responders and nonresponders to anti-programmed cell death-1 (PD-1) therapy. Survival analysis established the role of Yin Yang 1 (YY1) in determining ICI efficacy. Coculture models of hepatoma and CD8

Indexed as

hepatocellular carcinomaimmune checkpoint inhibitorspolypeptide N‐acetylgalactosaminyltransferase 16programmed death ligand‐1 glycosylationYin Yang 1

Identifiers

PMID41322030
PMCPMC12658286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.